Baylor College of Medicine

TEXAS-DEVELOPED PATENT-FREE COVID-19 VACCINE TECHNOLOGY RECEIVES EMERGENCY USE AUTHORIZATION IN INDONESIA

Retrieved on: 
Friday, September 30, 2022

Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.

Key Points: 
  • Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.
  • Indonesia is seeking Halal Certification for the vaccine since no animal cells or products were used in the production of the vaccine.
  • The pharmaceutical company is currently manufacturing Covid-19 primary series vaccine, while booster vaccine is in the clinical trial stage and soon followed by vaccine for children.
  • Bio Farma became a holding company after a merger of three listed state-owned pharmaceutical companies in Indonesia.

Final Call To Apply For The 2022 Biocodex Microbiota Foundation $50,000 U.S. Research Grant

Retrieved on: 
Monday, September 26, 2022

BEDMINSTER, N.J.,  September 26, 2022 /PRNewswire-PRWeb/ -- With the submission deadline approaching, the Biocodex Microbiota Foundation is calling for final grant applications from early-career investigators studying gut microbiota in human health and disease, including Covid-19, sleep disorders, the brain-gut axis and other evolving gut health research. The $50,000 research grant, now in its 6th year, is juried by a panel of medical and scientific experts in the field and can be applied to a new or existing study. The application can be downloaded here and deadline for entry is October 1, 2022, 5PM EST.

Key Points: 
  • This is the sixth consecutive year the Biocodex Microbiota Foundation has awarded the $50,000 US grant, which aims to advance research and understanding of human microbiota.
  • Other Biocodex Microbiota Foundation $50,000 grant recipients include:
    The Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to recognize the interaction between microbiota and different pathologies.
  • To learn more information about Biocodex Microbiota Foundation and the 2022 US grant program, click here .
  • About the Biocodex Microbiota Foundation:
    The Biocodex Microbiota Foundation's mission is to support research into microbiota and its interaction with various pathologies.

Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle

Retrieved on: 
Friday, September 23, 2022

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Key Points: 
  • HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
  • This historic donation is being made to commemorate the Blue Bird Circle's upcoming centennial anniversary and brings the organization's gifts to Texas Children's to over $25 million which will help advance life-changing neurological research at the Duncan NRI.
  • At Texas Children's Hospital Blue Bird Clinic, Blue Bird volunteers log more than 5,000 hours a year in administrative assistance the equivalent of three full-time employees.
  • The volunteers' time, effort, and donations help support The Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital.

Ellison Institute Welcomes Dr. Reva Basho as new Director of the Women's Cancer Program

Retrieved on: 
Wednesday, September 21, 2022

LOS ANGELES, Sept. 21, 2022 /PRNewswire/ -- The Lawrence J. Ellison Institute for Transformative Medicine announced today the appointment of Dr. Reva Basho as the Institute's new Director of the Women's Cancer Program.

Key Points: 
  • LOS ANGELES, Sept. 21, 2022 /PRNewswire/ -- The Lawrence J. Ellison Institute for Transformative Medicine announced todaythe appointmentof Dr. Reva Basho as the Institute's new Director of the Women's Cancer Program.
  • "We are thrilled to have Dr. Basho join our growing Institute team as both a highly skilled clinician and researcher," said Dr. David Agus, Founding Director and CEO of the Ellison Institute.
  • "I'm incredibly excited to join the Ellison Institute to help build a leading Women's Cancer Program," said Dr.
  • Dr. Basho joins the Institute from Cedars-Sinai Medical Center, where she served as the Co-Director of the Women's Cancer Research Program.

Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

Retrieved on: 
Wednesday, September 14, 2022

SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .

Key Points: 
  • SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .
  • The ACGTEA 2022 Awards were held in conjunction with the 6th Cell & Gene Therapy World Asia 2022.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.

CCRM Fertility Expands Houston Clinic with Addition of Dr. Beth Zhou

Retrieved on: 
Tuesday, September 13, 2022

HOUSTON, Sept. 13, 2022 /PRNewswire/ -- CCRM Fertility, a global pioneer in fertility treatment, research and science, today announced Dr. Beth Zhou, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology, has joined CCRM Houston following her fellowship at University of California, San Diego (UCSD) in La Jolla, Calif. Dr. Zhou is currently accepting new patients.

Key Points: 
  • "CCRM Fertility has always been committed to building, growing and maintaining a team of physicians that share the same passion and attentiveness to personalized fertility care," said Jon Pardew, president and CEO of CCRM Fertility.
  • Dr. Zhou is a native Houstonian and attended the University of Houston where she received her bachelor's degree in biology magna cum laude.
  • Dr. Zhou practices out of the following locations: 929 Gessner Rd., Suite 2300, Houston, TX 77024 and 7400 Fannin, Suite 910, Houston, TX 77054.
  • CCRM Fertility is a global pioneer in fertility treatment, research and science.

Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines

Retrieved on: 
Sunday, September 11, 2022

After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.

Key Points: 
  • After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.
  • All Covid-19 vaccines made by Bio Farma, including the primary series vaccines, booster vaccines and vaccines for children, will be labelled IndoVac.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like Bill and Melinda Gates Foundation (BMGF), PATH and the WHO.
  • Bio Farma has since become the main supplier of polio vaccines in the world, and currently contributes 67 percent to the global supply of polio vaccines.

Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development

Retrieved on: 
Tuesday, September 6, 2022

Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round.

Key Points: 
  • Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, today announced the close of a $220 million Series B financing round.
  • Proceeds from the financing will help the company expand its programmable cell therapy research activities and grow its pipeline of therapeutic candidates for solid tumor malignancies across a range of cancer indications.
  • The company also has candidates in early development for kidney, prostate, and other cancer indications.
  • Arsenal Biosciences, Inc. (ArsenalBio), headquartered in South San Francisco, Calif., is a privately held programmable cell therapy company discovering and developing a pipeline of next-generation autologous T cell therapies to defeat cancer.

Perimeter Medical Imaging AI Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 24, 2022

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (Perimeter or the Company) a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs today reported financial results for its second quarter ended June 30, 2022 and provided a corporate update.

Key Points: 
  • Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (Perimeter or the Company) a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs today reported financial results for its second quarter ended June 30, 2022 and provided a corporate update.
  • Patient recruitment continues into a multi-center, randomized two-arm pivotal clinical trial evaluating Perimeter B-Series OCT combined with proprietary ImgAssist AI software.
  • The Company will host a conference call and live audio webcast today, August 24, 2022, at 5:00 pm Eastern Time to discuss its second quarter results and to provide a corporate update.
  • About Perimeter Medical Imaging AI, Inc.
    Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.

Dr. Rod J. Rohrich Recognized by Newsweek as the Best Rhinoplasty Surgeon in the United States for the Second Consecutive Year

Retrieved on: 
Tuesday, August 23, 2022

DALLAS, Aug. 23, 2022 /PRNewswire-PRWeb/ -- Renowned rhinoplasty specialist, Dr. Rod J. Rohrich was recently ranked as the best rhinoplasty surgeon in the United States for the second consecutive year in Newsweek's recently published peer reviewed list of top performing plastic surgeons.

Key Points: 
  • Dallas plastic surgeon and rhinoplasty specialist, Dr. Rod J. Rohrich, has been recognized again as the best rhinoplasty surgeon in the United States by Newsweek.
  • DALLAS, Aug. 23, 2022 /PRNewswire-PRWeb/ -- Renowned rhinoplasty specialist, Dr. Rod J. Rohrich was recently ranked as the best rhinoplasty surgeon in the United States for the second consecutive year in Newsweek's recently published peer reviewed list of top performing plastic surgeons.
  • Dr. Rohrich was ranked in the first position at number 1 for best rhinoplasty surgeons in the United States, with the top score of 94.64% based on the scoring system.
  • He was named the top plastic surgeon in America by Newsweek in both rhinoplasty and facelift surgery in 2021 and 2022.